Prevalence of NAFLD in T1DM Patients

The Prevalence of Non-Alcoholic Fatty Liver Disease in Type 1 Diabetes Mellitus Patients Followed at Ziekenhuis Oost-Limburg, Genk, Belgium

Status

Recruiting

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06445361

Acronym

PAD1ZOL

Enrollment

138

Registered

2024-06-06

Start date

2023-07-01

Completion date

2026-07-01

Last updated

2025-07-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fatty Liver, Nonalcoholic, NAFLD, Type 1 Diabetes

Brief summary

To determine the prevalence of NAFLD in T1DM patients.

Interventions

DIAGNOSTIC_TESTFibroScan

Performance of a FibroScan measurement to determine steatosis and fibrosis.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* T1DM * ≥ 18 years of age * Written informed consent obtained

Exclusion criteria

* Excessive alcohol use * Exclusion of other causes of liver disease and secondary causes of liver steatosis

Design outcomes

Primary

Measure	Time frame	Description
Prevalence of NAFLD in T1DM	During the intervention	To determine the prevalence of steatosis in a cohort of T1DM patients followed at the Departments of Endocrinology in ZOL by means of the FibroScan® device with controlled attenuation parameter (CAP) measurements.
Prevalence of fibrosis in T1DM	During the intervention	To determine the prevalence of fibrosis in a cohort of T1DM patients followed at the Departments of Endocrinology in ZOL by means of the FibroScan® device with vibration controlled attenuation parameter (VCTE) measurements.

Countries

Belgium

Contacts

Primary ContactLeen Heyens, MsC

nafldstudie@zol.be089 21 20 55

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026